---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-122862"
form_type: "8-K"
ticker: null
cik: "0001292519"
company_name: "INVIVO THERAPEUTICS HOLDINGS CORP."
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:14:31.249976+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# InVivo Therapeutics receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until May 29, 2024

## Summary
- Company's common stock bid price closed below $1.00 per share for 30 consecutive business days.
- Initial 180-day compliance period ends May 29, 2024; must close at $1.00+ for 10 consecutive days.
- If compliance not achieved, Nasdaq may delist; company can appeal to Listing Qualifications Panel.
- Company may be eligible for an additional 180-day cure period if it meets other listing standards.
- Options considered include monitoring bid price and potential reverse stock split to regain compliance.

## SEC filing metadata
- accession: 0001104659-23-122862
- form_type: 8-K
- cik: 0001292519
- company_name: INVIVO THERAPEUTICS HOLDINGS CORP.
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1292519/000110465923122862/0001104659-23-122862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1292519/000110465923122862/tm2332011d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-122862
- JSON: https://secwatch.observer/filing/0001104659-23-122862.json
- Plain text: https://secwatch.observer/filing/0001104659-23-122862.txt

## Key facts
- Listing & Compliance Notices
  INVIVO THERAPEUTICS HOLDINGS CORP. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: December 1, 2023, InVivo Therapeutics Holdings Corp. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1292519/000110465923122862/0001104659-23-122862-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.